United States securities and exchange commission logo





                             May 1, 2023

       Wallace Lee
       Chief Financial Officer
       Bon Natural Life Limited
       25F, Rongcheng Yungu
       Keji 3rd Road
       Xi'an Hi-Tech Zone
       Xi'an, China

                                                        Re: Bon Natural Life
Limited
                                                            Form 20-F for the
Fiscal Year Ended September 30, 2022
                                                            Filed February 10,
2023
                                                            File No. 001-40517

       Dear Wallace Lee:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 20-F for the Fiscal Year Ended September 30, 2022

       Part I, Item 3. Key Information, page 2

   1.                                                   At the onset of Part I,
Item 3 disclose prominently that you are not a Chinese operating
                                                        company but a Cayman
Islands holding company with operations conducted by your
                                                        subsidiaries based in
China and that this structure involves unique risks to investors.
                                                        Provide a
cross-reference to your detailed discussion of risks facing the company and the
                                                        offering as a result of
this structure.
   2.                                                   Please provide
prominent disclosure about the legal and operational risks associated with
                                                        being based in or
having the majority of the company   s operations in China. Your
                                                        disclosure should make
clear whether these risks could result in a material change in your
                                                        operations and/or the
value of your securities or could significantly limit or completely
 Wallace Lee
FirstName
Bon NaturalLastNameWallace  Lee
             Life Limited
Comapany
May  1, 2023NameBon Natural Life Limited
May 1,
Page 2 2023 Page 2
FirstName LastName
         hinder your ability to offer or continue to offer securities to
investors and cause the value
         of such securities to significantly decline or be worthless. Your
disclosure should address
         how recent statements and regulatory actions by China   s government,
such as those
         related to data security or anti-monopoly concerns, have or may impact
the company   s
         ability to conduct its business, accept foreign investments, or list
on a U.S. or other
         foreign exchange.
3.       Please disclose whether your auditor is subject to the determinations
announced by the
         PCAOB on December 16, 2021 and whether and how the Holding Foreign
Companies
         Accountable Act and related regulations will affect your company.
Disclose that the
         HFCAA timeline for a potential trading prohibition was shortened from
three years to two
         years, as part of the "Consolidated Appropriations Act, 2023," signed
into law on
         December 29, 2022. Also, revise your risk factor disclosure on page 17
to explain the
         shortened timeframe.
4.       Please provide a clear description of how cash is transferred through
your organization.
         Disclose your intentions to distribute earnings. Quantify any cash
flows and transfers of
         other assets by type that have occurred between the holding company
and its subsidiaries,
         and direction of transfer. Quantify any dividends or distributions
that a subsidiary have
         made to the holding company and which entity made such transfer, and
their tax
         consequences. Similarly quantify dividends or distributions made to
U.S. investors, the
         source, and their tax consequences. Your disclosure should make clear
if no transfers,
         dividends, or distributions have been made to date. Describe any
restrictions on foreign
         exchange and your ability to transfer cash between entities, across
borders, and to U.S.
         investors. Describe any restrictions and limitations on your ability
to distribute earnings
         from the company, including your subsidiaries, to the parent company
and U.S. investors.
5.       Disclose each permission or approval that you or your subsidiaries are
required to obtain
         from Chinese authorities to operate your business and to offer
securities to foreign
         investors. State whether you or your subsidiaries are covered by
permissions requirements
         from the China Securities Regulatory Commission (CSRC), Cyberspace
Administration of
         China (CAC) or any other governmental agency that is required to
approve your
         operations, and state affirmatively whether you have received all
requisite permissions or
         approvals and whether any permissions or approvals have been denied.
Please also
         describe the consequences to you and your investors if you or your
subsidiaries: (i) do not
         receive or maintain such permissions or approvals, (ii) inadvertently
conclude that such
         permissions or approvals are not required, or (iii) applicable laws,
regulations, or
         interpretations change and you are required to obtain such permissions
or approvals in the
         future.
Item 3. Key Information, D. Risk Factors, page 3

6.       At the onset of your risk factor discussion, please add a risk factor
that addresses your
         corporate structure and being based in or having the majority of the
company   s operations
         in China. Discuss the risks it poses to investors. In particular,
describe the significant
 Wallace Lee
FirstName
Bon NaturalLastNameWallace  Lee
             Life Limited
Comapany
May  1, 2023NameBon Natural Life Limited
May 1,
Page 3 2023 Page 3
FirstName LastName
         regulatory, liquidity, and enforcement risks. For example,
specifically discuss risks arising
         from the legal system in China, including risks and uncertainties
regarding the
         enforcement of laws and that rules and regulations in China can change
quickly with little
         advance notice; and the risk that the Chinese government may intervene
or influence your
         operations at any time, or may exert more control over offerings
conducted overseas
         and/or foreign investment in China-based issuers, which could result
in a material change
         in your operations and/or the value of your securities. Acknowledge
any risks that any
         actions by the Chinese government to exert more oversight and control
over offerings that
         are conducted overseas and/or foreign investment in China-based
issuers could
         significantly limit or completely hinder your ability to offer or
continue to offer securities
         to investors and cause the value of your securities to significantly
decline or be worthless.
Item 15. Controls and Procedures
A. Disclosure Controls and Procedures , page 102

7.       Item 15(a) of Form 20-F requires you to disclose the conclusions of
your principal
         executive and principal financial officers, or persons performing
similar functions,
         regarding the effectiveness of your disclosure controls and
procedures. Please note that
         disclosure controls and procedures and internal control over financial
reporting require
         two separate and distinct assessments and conclusions. Please amend
the filing to include
         management   s assessment of the effectiveness of disclosure controls
and procedures as of
         September 30, 2022 as required by Item 15(a) of Form 20-F.
B. Management's Annual Report on Internal Control Over Financial Reporting,
page 102

8.       You state this annual report does not include a report of management
s assessment
         regarding internal control over financial reporting due to the
transition period established
         by rules of the SEC for newly public companies. However, we note that
you filed an
         annual report on Form 20-F for the year ended September 30, 2021
pursuant to Section
         13(a) or 15(d) of the Exchange Act. Please amend your filing to
include management   s
         report on internal control over financial reporting for the year ended
September 30, 2022.
         Refer to Item 15(b) and Instruction 1 to Item 15 of Form 20-F.
Exhibits

9.       Your certifications filed as Exhibit 31.1 and 31.2 appear to include
modifications from the
         standard language, including paragraph 4(d). In the amended filing and
other future
         filings, please revise these certifications to include the exact
language as provided in
         Exhibit Instruction 12 to Form 20-F.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 Wallace Lee
Bon Natural Life Limited
May 1, 2023
Page 4

       You may contact Gary Newberry at (202) 551-3761 or Tara Harkins,
Reviewing
Accountant at (202) 551-3639 if you have questions regarding comments on the
financial
statements and related matters. Please contact Arzhang Navai at (202) 551-4676
or Joe McCann,
Legal Branch Chief, at (202) 551-6262 with any other questions.



FirstName LastNameWallace Lee                            Sincerely,
Comapany NameBon Natural Life Limited
                                                         Division of
Corporation Finance
May 1, 2023 Page 4                                       Office of Life
Sciences
FirstName LastName